Table 2 Activity of bortezomib in tumor models in vivo.
From: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Cancer | Activity | MTD | References |
|---|---|---|---|
Multiple myeloma | Decreased tumor growth and angiogenesis; increased survival | 0.5 mg/kg IV twice weekly for 4 weeks | LeBlanc et al [43], 2002 |
Adult T-cell leukemia | Decreased or no effect on tumor growth | 1.0 mg/kg IP twice weekly for 2 weeks | Tan and Waldmann [19], 2002 Satou et al [44], 2004 |
Lung | Tumor growth delay and decreased lung metastases | 1.0 mg/kg PO once daily for 18 days | Teicher et al [45], 1999 |
Breast | Decreased surviving fraction of tumor cells | 5.0 mg/kg IP once | Teicher et al [45], 1999 |
Prostate | Decreased tumor growth; decrease or no effect on angiogenesis | 1.0 mg/kg IV weekly for 4 weeks, or q 72 hrs for 15 days | Adams et al [13], 1999 Williams et al [46], 2003 |
Pancreatic | Decreased or no effect on tumor growth and angiogenesis; increased or no effect on tumor apoptosis | 1.0 mg/kg IV biweekly for 2 to 3 weeks, or weekly for 4 weeks or 0.25 mg/kg IP biweekly for 4 weeks | Shah et al [24], 2001 Nawrocki et al [47], 2002 Bold et al [48], 2001 |
Head and neck | Decreased tumor growth and angiogenesis | 1.5 mg/kg IP 3 times per week for 3 weeks | Sunwoo et al [17], 2001 |
Colon | Decreased tumor growth and increased tumor apoptosis | 1.0 mg/kg IV twice weekly | Cusack et al [30], 2001 |
Melanoma | Decreased tumor growth and angiogenesis; increased tumor apoptosis | 1.25 mg/kg SC twice weekly for 5 weeks | Amiri et al [49], 2004 |